ScholarLens Back to search
2009•OncologyRequires access

Randomized Trial of Tamoxifen versus Aminoglutethimide and versus Combined Tamoxifen and Aminoglutethimide in Advanced Postmenopausal Breast Cancer

M.C. Alonso-Muñoz, M.B. Ojeda-González, Miquel Beltran-Fabregat, J. Dorca-Ribugent, Laura López‐López, J. Borrás-Balada, F. Cardenal-Alemany, Xavier Gómez‐Batiste, J. Fabregat-Mayol, P. Viladiu-Quemada

Open publisher page 41 citations

Abstract

In a randomized trial, 105 postmenopausal women with advanced carcinoma of the breast received tamoxifen or aminoglutethimide or combined tamoxifen and aminoglutethimide. No differences were found in the rate of responses and duration of responses between the treatment groups. Toxicity was significantly greater (p less than 0.01) in patients who received aminoglutethimide.

About this research paper

What this paper is about

In a randomized trial, 105 postmenopausal women with advanced carcinoma of the breast received tamoxifen or aminoglutethimide or combined tamoxifen and aminoglutethimide. No differences were found in the rate of responses and duration of responses between the treatment groups. Toxicity was significantly greater (p less than 0.01) in patients who received aminoglutethimide.

Why it matters

OpenAlex reports 41 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In a randomized trial, 105 postmenopausal women with advanced carcinoma of the breast received tamoxifen or aminoglutethimide or combined tamoxifen and aminoglutethimide. No differences were found in the rate of responses and duration of responses between the treatment groups. Toxicity was significantly greater (p less than 0.01) in patients who received aminoglutethimide.

Key concepts: Aminoglutethimide, Tamoxifen, Medicine, Randomized controlled trial, Breast cancer, Oncology, Antiestrogen, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Randomized Trial of Tamoxifen versus Aminoglutethimide and versus Combined Tamoxifen and Aminoglutethimide in Advanced Postmenopausal Breast Cancer — Research Paper | ScholarLens